None of these companies have a product to sell, but their stock prices have all increased 300% or more this year. Can they keep it up?
News & Analysis: Kite Pharma
Gilead Sciences CEO and oncology chief take on direct questions about why buying Kite was the right move.
News that the company agreed to be acquired by a biotech giant sent shares screaming higher.
The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.
These stocks gained in a mixed market. Find out why.
The biotechs' surge is related to a big move for fellow immuno-oncology drug developer Kite Pharma.
With the deal, the antiviral drug specialist dives headfirst into CAR-T cancer therapies.
Lumber Liquidators, Kite Pharma, and Weight Watchers have been the market's star performers so far this year.
Is Agenus or Kite Pharma the better oncology stock to own right now?
Kite Pharma, Celgene, and Acadia Pharmaceuticals are three biotech stocks that should be on enterprising investors' radars. Here's why.